期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单克隆抗体时代中期18~F-FDG PET/CT在弥漫大B细胞淋巴瘤中的应用价值研究进展 被引量：3

Role of Interim 18~F-FDG PET/CT Scanning for Diffuse Large B Cell Lymphoma in Rituximab Era
下载PDF
导出
摘要 正电子放射断层造影术-计算机断层摄影术(positron emission tomography-computed tomography,PET/CT)作为一种重要的无创性检查手段,在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)诊治过程中的作用举足轻重。在利妥昔单克隆抗体时代,PET/CT已替代传统CT检查,成为初诊患者精确分期和治疗过程中评估疗效的标准影像学检查。本文通过介绍中期PET/CT的定义、判读方法、预后价值及危险度分层来阐明中期PET/CT在DLBCL诊治过程中的驱动意义,并对近年来关于中期PET/CT驱动的治疗调整在临床中的应用进行综述。 As an important noninvasive diagnostic tool,the positron emission tomography/computed tomography（ PET/CT） plays a significant role in diagnosis and therapy of patients with diffuse large B-cell lymphoma（ DLBCL）.PET/CT,a standard imaging tool for initial accurate staging and response assessments,has replaced conventional CT in rituximab era. In this review,the definition,interpretation method,prognostic value and risk stratification of interim PET/CT are introduced to clarify the guiding significance of PET/CT in the diagnosis and theray of DLBCL,and the application of PET/CT scanning-guided prognostic factors and response-adapted therapy for DLBCL is summarized.
作者 陆晓林 朱海燕 于力
机构地区 中国人民解放军总医院血液科
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2017年第4期1241-1244,共4页 Journal of Experimental Hematology
关键词 中期PET/CT 弥漫大B细胞淋巴瘤 治疗调整 利妥昔单克隆抗体时代 interim PET/CT diffuse large B cell lymphoma response-adapted therapy rituximab era
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献31

  • 1Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphuma. N Engl Med 2002,346:235-42.
  • 2van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/ resistant follicular non-Hodgkin tymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-301.
  • 3Cabanillas F. Rituximab in DLBCL: 6 years on. Lancet Oncol 2011,12:984-5.
  • 4Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al., MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. Lancet Oncol 2006,7:379-91.
  • 5Yamaguchi H, Hirakawa T, lnokuchi K. Importance of relative dose intensity in chemotherapy for diffuse large B-Cell lymphoma. J Clin Exp Hematop 2011 ,51 : 1-5.
  • 6Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010,28:4184-90.
  • 7Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011,140:117-26.
  • 8Michallet AS, Lebras L, Coiffier B. Maintenance therapy in diffuse large B-cell lymphoma. Curr Opin Oncol 2012,24:461-5.
  • 9Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance tbr the treatment of patients with tbllicular lymphoma: systematic review' and meta-analysis of randomized trials. J Natl Cancer Inst 2009,101:248-55.
  • 10Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011,103:1799-806.

共引文献18

同被引文献12

引证文献3

二级引证文献8

中国实验血液学杂志
2017年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部